Anixa Bio says COVID-19 compounds may work against Omicron, shares rise

Anixa Biosciences

07/12/2021 14:08

** Shares of vaccine and therapy developer  ANIX.O  rise
4.8% to $3.28 premarket
    ** Anixa Biosciences and partner MolGenie say results of a
genomic variant analysis indicate their compounds in development
for the treatment of COVID-19 should be effective against the
Omicron as well as Delta variants  urn:newsml:reuters.com:*:nPn7PnThDa
    ** The companies are currently focused on developing an oral
pill for COVID-19 and are testing compounds that block Mpro - a
key enzyme needed for the virus to replicate
    ** No significant mutations of the Omicron variant are found
in or near the active site of the Mpro enzyme, says ANIX
    ** Stock had risen nearly 2% YTD, up to the last close

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))